View Older Stories View More Recent Stories
-
Johnson & Johnson reports positive results for TECVAYLI in myeloma study
-
Johnson & Johnson presents depression research at neuroscience meeting
-
Johnson & Johnson reports extended colorectal cancer study results
-
HSBC lists 11 potential U.S. outperformers heading into earnings
-
Bernstein Highlights Top U.S. Medtech 2026 Picks: 'Sector Poised For a Rebound'
-
Johnson & Johnson (JNJ) Reaches Agreement with U.S. Govt to Lower Drug Costs
-
Johnson & Johnson (JNJ) call put ratio 2.7 calls more active than puts into the annual J.P. Morgan Healthcare Conference
-
Lexeo partners with Johnson & Johnson on cardiac gene therapy delivery
-
Johnson & Johnson (JNJ) PT Raised to $205 at Stifel
-
UBS Reiterates Buy Rating on Johnson & Johnson (JNJ), Highlights Strong Fundamentals
-
Goldman Sachs: 'top themes we're tracking for 2026'
-
Johnson & Johnson (JNJ) PT Raised to $217 at Barclays
-
BTIG on Apogee (APGE): 'DUPLEX-AD's Failure is Likely a Clearing Event for APG279 and APG777 in Atopic Dermatitis'
-
Johnson & Johnson ends atopic dermatitis drug trial early over low efficacy
-
Johnson & Johnson gains European approval for psoriasis drug in children
-
Trump: Johnson and Johnson and four other companies will be coming in next week, they've agreed to lowest price in world
-
Trump to announce prescription drug price agreements
-
Goldman Weekly Options Watch
-
CFRA Downgrades Johnson & Johnson (JNJ) to Hold
-
Johnson & Johnson (JNJ) PT Raised to $230; RBC Capital: 'We See Upside'
-
RBC Capital Defends Legend (LEGN) For Second Day in a Row As Stock Continues to Push Lower
-
J&J's INLEXZO shows 74% disease-free survival in bladder cancer study
-
Johnson & Johnson (JNJ) PT Raised to $227 at Guggenheim
-
Johnson & Johnson (JNJ) tops $500B in valuation
-
Guggenheim Reiterates Buy Rating on Johnson & Johnson (JNJ)
-
FDA grants traditional approval to daratumumab and hyaluronidase-FIHJ for newly diagnosed light chain amyloidosis
-
Johnson & Johnson reports 48-week data for TREMFYA in psoriatic arthritis
-
Johnson & Johnson to acquire Halda Therapeutics for $3.05 billion
-
Judge denies Texas AG's TRO against Kenvue over Tylenol marketing
-
FDA approves DARZALEX FASPRO for high-risk smoldering multiple myeloma
-
Johnson & Johnson seeks FDA approval for STELARA in pediatric ulcerative colitis
-
HHS Secretary Kennedy on Tylenol: not enough evidence to show Tylenol definitively causes autism but some studies seem 'very suggestive'
-
Johnson & Johnson initiates first head-to-head FcRn blocker study for myasthenia gravis
-
Texas attorney general sues Johnson & Johnson and Kenvue over Tylenol marketing
-
Johnson & Johnson reports extended trial results for ulcerative colitis drug
-
TREMFYA shows sustained remission in Crohn's disease at two years
-
Johnson & Johnson reports 52-week psoriasis trial results for icotrokinra
-
Freedom Capital Markets Downgrades Johnson & Johnson (JNJ) to Hold
-
Stifel Reiterates Bicara Therapeutics Inc (BCAX) at Buy, Still Confident of Ficerafusp Thesis
-
Guggenheim Reiterates Buy Rating on Johnson & Johnson (JNJ)
-
J&J drug combination shows survival benefits in myeloma study
-
Johnson & Johnson (JNJ) PT Raised to $201 at Leerink Partners, 'Improving Growth Prospects'
-
RBC Capital Reiterates Outperform Rating on Johnson & Johnson (JNJ)
-
Johnson & Johnson (JNJ) PT Raised to $209 at Raymond James
-
Johnson & Johnson (JNJ) PT Raised to $225 at Wolfe Research
-
Johnson & Johnson (JNJ) PT Raised to $190 at Stifel
-
Johnson & Johnson (JNJ) PT Raised to $215 at Citi
-
CFRA Upgrades Johnson & Johnson (JNJ) to Buy
-
Johnson & Johnson (JNJ) call put ratio 2 calls to 1 put amid plans to separate Orthopaedics business and quarter outlook
-
J&J raises revenue guide as Q3 tops forecasts, plans to spin off Orthopaedics unit
